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Chromosome 4q25 Variants and
Atrial Fibrillation Recurrence After Catheter Ablation
Daniela Husser, MD,* Volker Adams, PHD,† Christopher Piorkowski, MD,* Gerhard Hindricks, MD,*
Andreas Bollmann, MD, PHD*
Leipzig, Germany
Objectives This study tested the hypothesis that chromosome 4q25 single-nucleotide polymorphisms (SNPs) associate with
atrial fibrillation (AF) recurrence after catheter ablation.
Background Recent genome-wide association studies identified 2 SNPs on chromosome 4q25 associated with AF. Although
the mechanisms underlying this increased risk are unknown, the closest gene, PITX2, is critical for myocardium
development in the pulmonary veins.
Methods A total of 195 consecutive patients (mean age 56  12 years, 73% male) with drug-refractory paroxysmal
(78%) or persistent (22%) AF who underwent AF catheter ablation were included. Two SNPs, rs2200733
and rs10033464, were genotyped using real-time polymerase chain reaction and fluorescence resonance
energy transfer. Serial 7-day Holter electrocardiographic recordings were acquired to detect AF recurrences.
Results Early recurrence of atrial fibrillation (ERAF) (within the first 7 days) was observed in 37%, whereas late recur-
rence of atrial fibrillation (LRAF) (between 3 and 6 months) occurred in 21% of the patients. None of the clinical
or echocardiographic baseline characteristics were associated with ERAF or LRAF. In contrast, the presence of
any variant allele increased the risk for both ERAF (odds ratio [OR]: 1.994, 95% confidence interval [CI]: 1.036
to 3.837, p  0.039) and LRAF (OR: 4.182, 95% CI: 1.318 to 12.664, p  0.011). In patients with ERAF, 45%
had LRAF, as opposed to 8% in patients without ERAF (OR: 9.274, 95% CI: 3.793 to 22.678, p  0.001).
Conclusions Polymorphisms on chromosome 4q25 modulate the risk for AF recurrence after catheter ablation. This finding
points to a potential role for stratification of AF ablation therapy or peri-interventional management by
genotype. (J Am Coll Cardiol 2010;55:747–53) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.041m
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etrial fibrillation (AF) is a heterogeneous arrhythmia at
oth the clinical and the molecular levels. Association
tudies have reported that common single-nucleotide poly-
orphisms (SNPs) in genes encoding cardiac ion channels
1–3), the renin–angiotensin system (4), or connexin 40 (5)
ay predispose to AF development. Recently, a genome-
ide association study identified a haplotype block on
hromosome 4q25 containing 2 SNPs, rs2200733 and
s10033464, that predisposes to AF (6). This association
as replicated in several independent cohorts (7,8).
Although the molecular mechanisms underlying this
ncreased risk are unknown, future studies to determine
hether this SNP is associated with certain phenotypes or
utcomes have been suggested (7). In that respect it is
nteresting to note that the closest gene, PITX2, is a
ranscription factor critical for determining left–right asym-
rom the Departments of *Electrophysiology and †Cardiology, Heart Center,
eipzig, Germany. Dr. Husser was supported by the Volkswagen Foundation,
ermany, and research grants HU 1679/1-1, Deutsche Forschungsgemeinschaft, and
BL Formel.1-109, University of Leipzig, Germany.m
Manuscript received August 25, 2009; revised manuscript received October 20,
009, accepted November 10, 2009.etry (9) and the differentiation of the left atrium, and for
he development of the pulmonary myocardium (10). Pul-
onary myocardial sleeves are the source of ectopy associated
See page 754
ith AF initiation and maintenance in many cases, and their
lectrical disconnection from the left atrium is the therapeutic
arget of pulmonary vein ablation procedures. Accordingly, this
tudy examined the relationship between the 2 AF risk alleles
n chromosome 4q25 (rs2200733, rs10033464) and AF recur-
ence after catheter ablation of AF.
ethods
tudy population. In this study, 195 consecutive Cauca-
ian patients of German descent who underwent left atrial
atheter ablation for drug-refractory paroxysmal or persis-
ent AF were included. In all patients, transthoracic and
ransesophageal echocardiography was performed prior to
atheter ablation. Left atrial diameter and left ventricular
jection fraction were determined using standard measure-
ents, and a left atrial thrombus was excluded. All class I or
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with the exception of amioda-
rone were discontinued at least 5
half-lives before the procedure.
The study was approved by the
local ethics committee, and pa-
tients provided written informed
consent for participation.
Catheter ablation. Left atrial
catheter ablation was performed
using a previously described ap-
proach (11). In brief, patients were
studied under deep propofol seda-
ion with continuous invasive monitoring of arterial blood
ressure and oxygen saturation. The NavX-Ensite system
version 7.0, Endocardial Solutions, Inc., St. Paul, Minnesota)
as used for nonfluoroscopic 3-dimensional catheter orienta-
ion, computed tomographic image integration, and tagging of
he ablation sites with the coronary sinus lead 5/6 serving as
ystem reference. Transseptal access and catheter navigation
ere performed with a steerable sheath (Agilis, St. Jude
edical, Inc., St. Paul, Minnesota). Patients presenting with
F at the beginning of the procedure were electrically cardio-
erted, and ablation was performed during sinus rhythm (i.e.,
F termination with ablation was not attempted). In all
atients, circumferential left atrial ablation lines were placed
round the antrum of the ipsilateral pulmonary veins
irrigated-tip catheter, pre-selected tip temperature of 48°C,
nd maximum power of 30 to 50 W). In patients with
ersistent AF, additional linear lesions were added at the left
trial roof, the basal posterior wall, and the left atrial isthmus.
blation of complex fractionated electrograms was not
erformed.
After circumferential line placement, voltage and pace
apping along the ablation line were used to identify and
lose gaps. The isolation of all pulmonary veins with
idirectional block was verified with a multipolar circular
apping catheter and was defined as the procedural end
oint.
ollow-up. Class I and III antiarrhythmic drugs were not
einitiated after ablation. Oral anticoagulation was pre-
cribed for 6 months, and proton pump inhibitors were
dded for 4 weeks. All patients were followed up in the
utpatient clinic for 6 months after the ablation. During this
ollow-up period, 7-day Holter recordings were performed
mmediately after the ablation and at 3 and 6 months after
he ablation. Additional electrocardiograms and Holter
ecordings were obtained when patients’ symptoms were
uggestive of AF. An AF recurrence was defined as a
ocumented AF episode lasting longer than 30 s. Early
ecurrence of atrial fibrillation (ERAF) was defined as an
F episode during the first week after the ablation, which is
n alignment with previous definitions (12,13). This defini-
ion was also chosen because continuous Holter monitoring
as available for all patients for this time period. Late
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
ERAF  early recurrence of
atrial fibrillation
LRAF  late recurrence of
atrial fibrillation
OR  odds ratio
SNP  single-nucleotide
polymorphismecurrence of atrial fibrillation (LRAF) was defined as anyF episode between 3 and 6 months after the ablation (thus
ncluding a 3-month blanking period). All patients with
ustained early recurring AF underwent direct-current car-
ioversion. Additional drug administration was left to the
iscretion of the treating physician.
enotyping. The deoxyribonucleic acid was extracted
rom blood using a commercially available isolation kit
peqGOLD Blood DNA Mini Kit, PecLab, Erlangen,
ermany). For rapid genotyping of the 2 SNPs, real-time
olymerase chain reaction using fluorescence resonance
nergy transfer followed by the analysis of the melting curve
as applied as previously described (14). In brief, allele-
pecific, commercially synthesized primers and fluorescent
robes were used (TibMolBiol, Berlin, Germany) (Table 1).
ll samples were run in duplicates. A melting curve was
etected for each sample with distinctive peaks at different
emperatures. Based on these differences, a classification into
ild-type, heterozygous, or homozygous variant was per-
ormed (Fig. 1). A call rate of 98% was achieved with this
ethod for both variants. Genotypes were confirmed with
irect sequencing.
tatistical analysis. Continuous variables are reported as
ean  1 SD, and categorical variables are reported as
requencies. Continuous variables were compared using the
npaired Student t test, and categorical variables were
ompared using the chi-square test.
For genotype–rhythm outcome correlations, 3 different
odels were applied. The variant alleles were assumed to
ave dominant, recessive, or additive effects in these models.
n the dominant model, an identical effect is expected in
eterozygous and homozygous variant carriers. In the re-
essive model, an effect is only seen in homozygous variant
arriers, whereas in the additive model, heterozygous variant
arriers have an intermediate effect in relation to the
omozygotes.
Logistic regression analysis was used, and odds ratios
ORs) and their 95% confidence intervals (CIs) were calcu-
ated. Multivariable analysis that included pre-procedural
ariables (i.e., age, sex, AF duration, AF type, left atrial
iameter, left ventricular ejection fraction, antiarrhythmic
rug use, and genotypes) with a p value 0.15 found in
nivariate analysis was performed to identify independent
redictors of ERAF and LRAF.
ucleotide Sequences of the Primers, Anchors,nd Fluor sc nc R onance Energyransfer Probes for Both Variants
Table 1
Nu leotide Seque c s of the Primers, Anchors,
and Fluorescence Resonance Energy
Transfer Probes for Both Variants
Variant Primer/Probe Nucleotide Sequence (5=–3=)
rs10033464 Forward primer TCACAGCCGAGGATGTCTTTAGT
Reverse primer AGTTCTTGAGGAAAAGCCTGTTG
Anchor GCTCTGAGTTACAGAATTTATTAGAGTAAAGGG
Probe AGTCAAGAAATAAGTGCTTTCATCA-FL
rs2200733 Forward primer TCACACTTGACTCTCTACATGTCC
Reverse primer TGGATGAATGAATGAACTAGTGC
Anchor GGAGTAGTAATTCTGCCTTGGTGGTACTTG-FLProbe GTTTTGATTTTGATCAGAGAAAATTAGAA
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February 23, 2010:747–53 4q25 Variants and AF Ablation OutcomeA sample size calculation was performed assuming an AF
ecurrence rate of 20% and a minor allele frequency of 0.3.
n a dominant model, a sample size of 180 patients is
eeded to detect an OR of 2 for AF recurrence in variant
arriers with a power of 80%. A p value of 0.05 was
onsidered statistically significant without adjustment for
ultiple comparisons.
esults
atient characteristics and AF recurrence. Patient char-
cteristics are summarized in Table 2. The frequencies of
he rs10033464 and rs2200733 genotypes were GG in 68%,
T in 31%, and TT in 1%, and CC in 55%, CT in 35%,
nd TT in 10%, respectively. At least 1 variant allele was
resent in 68%, whereas no variant allele was found in 32%
f the study population (Table 3). There were no significant
ifferences in clinical and echocardiographic variables
mong different genotypes (Table 2). Complete pulmonary
ein isolation as a procedural end point was achieved in 191
atients (98%). All patients completed the 6-month follow-
p, including the 7-day Holter study. ERAF was observed
n 37%, whereas LRAF occurred in 21% of the patients.
Figure 1 Examples for Melting Curve Analysis for rs10033464
Fluorescent peaks at different temperatures resemble different genotypes. (Left) T
homozygous variant genotype is located at 64°C, and the heterozygous genotype r
type genotype is located at 64°C, the peak for the homozygous variant genotype is
at both temperatures.
atient CharacteristicsTable 2 Patient Characteristics
Total
(n  195)
rs10033464 GG
(n  132)
Age, yrs 56 12 56 12
Male/female (%) 73/27 72/28
Paroxysmal AF/persistent AF (%) 78/22 80/20
Lone AF (%) 83 84
AF history, months 72 67 70 69
LAD,* mm 43 7 42 6
LVEF, % 61 8 65 7n  190.
AF  atrial fibrillation; LAD  left atrial diameter; LVEF  left ventricular ejection fraction.ymptomatic AF requiring cardioversion between 3 and 6
onths was observed in 4%, whereas the remaining symp-
omatic and asymptomatic AF recurrences were detected
ith sequential 7-day Holter recordings.
None of the clinical or echocardiographic baseline char-
cteristics were significantly associated with ERAF or
RAF (Table 4). In particular, ERAF and LRAF rates
ere 37% and 22% for paroxysmal AF and 41% and 17% for
ersistent AF, respectively (p  NS for paroxysmal vs.
ersistent AF). Pre-procedural amiodarone was used in 17%
f the patients and was not associated with ERAF (42% vs.
8%, p  NS).
hromosome 4q25 variants and AF recurrence. In uni-
ariate analysis, the dominant and additive models for both
ariants showed a trend to be associated with ERAF,
hereas the dominant and additive model for the
s10033464 variant was significantly associated with LRAF
Table 5).
Multivariable analysis revealed that both variants were
ndependently predictive of ERAF and LRAF (Table 6).
he presence of any variant allele increased the risk for both
RAF (OR: 1.994, 95% CI: 1.036 to 3.837, p 0.039) and
s2200733 Genotypes of 3 Patients
orescent peak for the wild-type genotype is located at 57.7°C, the peak for the
in a double peaked curve at both temperatures. (Right) The peak for the wild-
ed at 56.7°C, and the heterozygous genotype results in a double-peaked curve
rs10033464 GT/TT
(n  63)
rs2200733 CC
(n  108)
rs2200733 CC/CT
(n  87)
56 10 55 12 57 12
76/24 71/29 76/24
76/24 80/20 77/23
83 83 84
75 62 69 67 75 67
44 8 43 7 44 8
57 8 58 9 65 5and r
he flu
esults
locat
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Fig. 2) compared with the wild type. In patients with ERAF
5% had LRAF, as opposed to 8% in patients without ERAF
OR: 9.274, 95% CI: 3.793 to 22.678, p  0.001).
iscussion
ain findings. To the best of our knowledge, this study is
he first to explore the association between AF risk alleles
nd AF recidivism after catheter ablation. Based on the
nalysis of 195 patients, it was clearly shown that 2 variants
n chromosome 4q25 were independently associated with
n increased risk for ERAF and LRAF. The presence of
RAF was associated with LRAF.
RAF after catheter ablation. An AF recurrence within
8 h (12) to 1 month (13) after catheter ablation is a common
bservation, with a reported prevalence of 35% to 52%
12,13,15,16), which is in alignment with our observed event
ate. There is general agreement that ERAF is associated with
orse rhythm outcome during the long-term follow-up, al-
hough the proportion of delayed cure varies substantially
12,13,15,16). A recent study reported freedom from AF in as
ow as 9% of patients with early recurrence (13), whereas
revious investigators found freedom from AF in 31% to 46%
f cases despite early recurrence (12,15), which is in close
greement to what we have observed in this study.
The pathophysiology of ERAF is complex and poorly
nderstood. Left atrial radiofrequency ablation has a proin-
ammatory effect (17) and modifies the autonomic nervous
ystem by reducing vagal activity and increasing sympathetic
ctivity (18), thereby being a stimulus for AF initiation early
fter ablation. However, a delayed beneficial effect second-
ry to scar consolidation may explain later freedom from AF
espite early AF recidivism. Although 1 study identified
lder patients’ age, the presence of cardiovascular disease,
he presence of AF foci (especially from the left atrial free
all), and left atrial enlargement as contributing factors for
aplotype Frequencies (%)Table 3 Haplotype Frequencies (%)
rs2200733 GG rs2200733 CT rs2200733 TT
rs10033464 GG 32.3 25.6 9.7
rs10033464 GT 22.1 8.7 0.5
rs10033464 TT 1.0
linical and Echocardiographic Characteristics in Patients WithoutTable 4 Clinical and Echocardiographic Characteristics in Patie
Without ERAF
(n  122)
With ERAF
(n  73)
Age, yrs 55 12 56 11
Male/female (%) 71/29 77/23
Paroxysmal AF/persistent AF (%) 80/20 77/23
Lone AF (%) 83 85
AF history, months 70 66 78 66
LAD, mm 43 7 44 5
LVEF, % 62 9 60 6RAF  early recurrence of atrial fibrillation; LRAF  late recurrence of atrial fibrillation; other abbreviatRAF (16), more research on its potential predictors and
rognostic implications clearly is warranted (13).
enetic variants, AF phenotypes, and response to
herapy. Over the last several years, data have emerged to
upport a genetic contribution to AF. Although several
enetic loci for familial forms of AF have been identified,
he genes responsible for AF at these loci remain unknown
19,20). Mutations in the cardiac sodium (21) and potas-
ium (22) channel complexes and gap junction proteins (23)
ave been identified to cause AF, although this accounts for
nly a small fraction of AF cases. In addition to several
andidate-gene association studies (1–4), recent genome-
ide association studies identified 2 common variants on
hromosome 4q25 that increase the risk for AF develop-
ent (6–8).
The prevalence of 4q25 variants has been analyzed in
ifferent AF populations, and ranges between 26% and 41%
or the rs2200733 SNP and between 19% and 22% for the
s10033464 SNP (7). Interestingly, the prevalence was
omewhat higher for both variants (45% and 32%, respec-
ively) in our cohort. This may be because we included a
ighly selected AF population, with most patients suffering
rom drug-refractory, paroxysmal lone AF. However, most
atients were referred from a localized geographic area, and
he prevalence of the 4q25 variants in the general population
n this area may also be higher but is currently not known.
In contrast to the aforementioned research avenue, there
ave been only very few studies that have evaluated the
orrelation of genetic variants, AF phenotypes, and response
o AF therapies. For instance, Firouzi et al. (5) demon-
trated increased dispersion of atrial refractoriness in pa-
ients with structurally normal hearts who carried the AA
enotype of the connexin 40-promoter polymorphism. Ehr-
ich et al. (24) found that the KCNE1 38G isoform was
ssociated with reduced IKs, which in turn leads to longer
trial action potential duration and refractoriness. Data
rom our group are in keeping with these findings. We
ound lower AF rates on the surface electrocardiogram in
ndividuals carrying the KCNE1 GG genotype (25). Finally,
single study has assessed the relationship between an
F-associated variant and the response to antiarrhythmic
edication (26). In that study of 213 AF patients, it was
hown that the ACE I/D polymorphism modulates the
With ERAF and LRAFithout and With ERAF and LRAF
p Value
Without LRAF
(n  155)
With LRAF
(n  40) p Value
0.57 56 11 57 13 0.88
0.41 74/26 79/21 0.45
0.65 76/24 82/18 0.39
0.73 86 88 0.78
0.42 72 70 74 60 0.62
0.49 43 8 43 9 0.92
0.16 63 8 56 6 0.08andntsions as in Table 2.
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February 23, 2010:747–53 4q25 Variants and AF Ablation Outcomeesponse to antiarrhythmic drugs, with the ID/DD geno-
ype being a strong predictor for drug failure.
In the present study, we analyzed the effects of 2 common
F-associated SNPs (rs2200733, rs10033464) and found
hat they modulate the response to catheter ablation. Both
ariants were independently predictive of ERAF and LRAF
sing dominant genetic models. Carriers of at least 1 variant
llele had a 4-fold increased risk for LRAF. However,
echanisms by which these variants exert functional effects
nd consequently why they predict rhythm outcome after
atheter ablation remain elusive. Initially, it has been spec-
lated that the close proximity of these variants to the
ITX2 gene, which has a critical function in cardiac
evelopment, may be one underlying mechanism for AF
evelopment (6). The PITX2 expression identifies the left
trium during embryonic development, whereas other tran-
Chromosome 4q25 Variants and AF RecurrenceTable 5 Chromosome 4q25 Variants and AF
AF, n (%)
ERAF
rs10033464 dominant
GG (n  132) 44 (33)
GT/TT (n  63) 29 (46)
rs10033464 additive
GG (n  132) 44 (33)
GT (n  61) 28 (46)
TT (n  2) 1 (50)
rs2200733 recessive
CC/CT (n  175) 64 (37)
TT (n  20) 9 (45)
rs2200733 dominant
CC (n  108) 34 (32)
CT/TT (n  87) 39 (45)
rs2200733 additive
CC (n  108) 34 (32)
CT (n  67) 30 (45)
TT (n  20) 9 (45)
LRAF
rs10033464 dominant
GG (n  132) 21 (16)
GT/TT (n  63) 19 (30)
rs10033464 additive
GG (n  132) 21 (16)
GT (n  61) 18 (30)
TT (n  2) 1 (50)
rs2200733 recessive
CC/CT (n  175) 36 (21)
TT (n  20) 4 (20)
rs2200733 dominant
CC (n  108) 18 (17)
CT/TT (n  87) 22 (26)
rs2200733 additive
CC (n  108) 18 (17)
CT (n  67) 18 (27)
TT (n  20) 4 (20)
AF  atrial fibrillation; CI  confidence interval; OR  odds ratio; othecription factors (e.g., Nkx2-5) determine its electrophysi- llogical properties, including the capability of automatic
mpulse formation (10).
In a recent series of animal experiments, it has been
hown that PITX2 also plays a key role in the differentia-
ion, proliferation, and expansion of pulmonary myocardial
ells (10). Of particular interest is the finding that PITX2-
eficient mice did not develop pulmonary myocardial
leeves as one distinctive pulmonary vein phenotype. Con-
idering this finding together with the data of the current
tudy, it is now tempting to speculate that chromosome
q25 variant carriers may differ in their pulmonary vein
henotype (i.e., amount, extension, and arrhythmogenicity
f pulmonary vein myocardium) and consequently on AF
echanisms, which will impact on catheter ablation of the
ulmonary veins. In other words, although catheter ablation
estricted to the pulmonary veins (with or without limited
ivariate Analysisurrence in Univariate Analysis
p Value OR 95% CI
0.088 1.706 0.924–3.15
0.091 1.653 0.923–2.96
0.462 1.419 0.558–3.608
0.057 1.768 0.984–3.177
0.083 1.461 0.952–2.243
0.038 2.288 1.048–4.997
0.031 2.227 1.078–4.6
0.908 0.925 0.245–3.49
0.132 1.812 0.835–3.931
0.283 1.356 0.777–2.356
viations as in Table 4.in UnRecinear lesions) may be sufficient in patients with the wild
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4q25 Variants and AF Ablation Outcome February 23, 2010:747–53ype, other ablation strategies or more aggressive post-
blation management may be warranted in variant carriers
n whom other atrial areas may be more important for AF
nduction and sustenance. This hypothesis is even further
ubstantiated by the fact that 4q25 variants also increase the
isk for atrial flutter, which is confined to the right atrium
6,8). Nevertheless, it must be pointed out that on the one
and, no direct mechanistic relationship between the chro-
osome 4q25 variants and PITX2 has been established; on
he other hand, the variants may also simply be a marker for
ther currently unidentified mechanisms independent of
ITX2 and consequently of the pulmonary veins.
Independent Pre-Procedural Predictors of AF ReTable 6 Independent Pre-Procedural Predict
p V
ERAF
Multivariable prediction model 1
rs10033464 dominant 0.0
rs2200733 dominant 0.0
Multivariable prediction model 2
rs10033464 additive 0.0
rs2200733 additive 0.0
LRAF
Multivariable prediction model 1
rs10033464 additive 0.0
rs2200733 dominant 0.0
Multivariable prediction model 2
rs10033464 dominant 0.0
rs2200733 dominant 0.0
Abbreviations as in Tables 4 and 5.
Figure 2 AF Recurrence After 6 Months
Stratified by the Presence of 4q25 Variants
Note the increased risk for atrial fibrillation (AF) recurrence (odds ratio: 4.182,
95% confidence interval: 1.318 to 12.664, p  0.011) if at least 1 4q25 vari-
ant was present compared with the wild type.aERAF also was associated with late recurrence. However,
his outcome parameter can only be acquired after ablation
uring early follow-up. Although adjustment of antiar-
hythmic therapy or early reablation (13) is possible when
his event occurs, one would like to predict the individual
isk or anticipated success rate before the procedure and to
lan the ablation strategy and post-ablation management
ccordingly.
tudy limitations. This study included a rather homoge-
eous patient population with a high proportion of lone
aroxysmal AF, and a standardized ablation approach was
pplied. Consequently, the generalizability of our findings
o other populations and the comparison with different
blation approaches, such as ablation of complex fraction-
ted electrograms (that we did not attempt), is uncertain.
nly 17% of our patients were on amiodarone before the
blation (which was not reinitiated after ablation). Although
miodarone treatment did not affect ERAF rates, our
ample size is too small to draw conclusions regarding its
ffects on AF recidivism after ablation and consequently
egarding the predictive value of the 4q25 variants in the
resence of antiarrhythmic drugs.
The follow-up period of our study was short, but later AF
ecurrences may be due to different mechanisms that are not
aptured with the analyzed variants. The presence of 1
ariant clearly increased the risk for AF recurrence, but
omozygous variant carriers represent only a minority of the
F population. To fully appreciate their risk, especially with
he rs10033464 variant, a larger sample is needed.
Although we have speculated that the variants point to
ifferent pulmonary vein phenotypes and consequently dis-
inct AF mechanisms, they also may be associated with
ulmonary vein reconduction, which is known to be the
revailing mechanism for AF recurrence (27). However,
ecause we did not perform re-ablations within the
-month follow-up interval, reconduction could not be
nce in Multivariable Analysisf AF Recurrence in Multivariable Analysis
OR 95% CI
2.081 1.087–3.986
2.108 1.135–3.917
2.027 1.091–3.766
1.693 1.074–2.668
2.821 1.294–6.146
2.458 1.061–5.693
2.881 1.252–6.634
2.379 1.035–5.468curreors o
alue
27
18
25
23
09
36
13
41ssessed.
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February 23, 2010:747–53 4q25 Variants and AF Ablation OutcomeUsing the candidate gene approach, this study was
imited to the investigation of 2 AF-associated SNPs. On
he one hand, initial testing was performed with different
enetic models with all inherent statistical limitations due to
he lack of previous data. On the other hand, other genes
ay also modulate atrial development, electrophysiology,
nd structure and consequently the response to AF thera-
ies. Most importantly, our findings need to be validated in
ifferent AF populations undergoing catheter ablation.
onclusions
he noncoding variants on chromosome 4q25, rs2200733
nd rs10033464, modulate the risk for AF recurrence after
atheter ablation. This finding points to a potential role for
tratification of ablation therapy or post-ablation manage-
ent by genotype.
cknowledgments
he authors thank Mrs. Angela Kricke and Mr. Markus
ehmann for their help with laboratory work.
eprint requests and correspondence: Dr. Daniela Husser,
epartment of Electrophysiology, Heart Center, Leipzig Univer-
ity, Strümpellstrasse 39, 04289 Leipzig, Germany. E-mail:
ani11@gmx.net.
EFERENCES
1. Lai LP, Su MJ, Yeh HM, et al. Association of the human minK gene
38G allele with atrial fibrillation: evidence of possible genetic control on
the pathogenesis of atrial fibrillation. Am Heart J 2002;144:485–90.
2. Fatini C, Sticchi E, Genuardi M, et al. Analysis of minK and eNOS
genes as candidate loci for predisposition to non-valvular atrial
fibrillation. Eur Heart J 2006;27:1712–8.
3. Chen LY, Ballew JD, Herron KJ, Rodeheffer RJ, Olson TM. A
common polymorphism in SCN5A is associated with lone atrial
fibrillation. Clin Pharmacol Ther 2007;81:35–41.
4. Tsai CT, Lai LP, Lin JL, et al. Renin-angiotensin system gene
polymorphisms and atrial fibrillation. Circulation 2004;109:1640–6.
5. Firouzi M, Ramanna H, Kok B, et al. Association of human
connexin40 gene polymorphisms with atrial vulnerability as a risk
factor for idiopathic atrial fibrillation. Circ Res 2004;95:e29–33.
6. Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring
risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:
353–7.
7. Kaab S, Darbar D, van Noord C, et al. Large scale replication and
meta-analysis of variants on chromosome 4q25 associated with atrial
fibrillation. Eur Heart J 2009;30:813–9.
8. Viviani Anselmi C, Novelli V, Roncarati R, et al. Association of
rs2200733 at 4q25 with atrial flutter/fibrillation diseases in an Italian
population. Heart 2008;94:1394–6. K9. Logan M, Pagan-Westphal SM, Smith DM, Paganessi L, Tabin CJ.
The transcription factor Pitx2 mediates situs-specific morphogenesis
in response to left-right asymmetric signals. Cell 1998;94:307–17.
0. Mommersteeg MT, Brown NA, Prall OW, et al. Pitx2c and Nkx2-5
are required for the formation and identity of the pulmonary myocar-
dium. Circ Res 2007;101:902–9.
1. Piorkowski C, Kircher S, Arya A, et al. Computed tomography
model-based treatment of atrial fibrillation and atrial macro-re-entrant
tachycardia. Europace 2008;10:939–48.
2. Richter B, Gwechenberger M, Socas A, Marx M, Gossinger HD.
Frequency of recurrence of atrial fibrillation within 48 hours after
ablation and its impact on long-term outcome. Am J Cardiol 2008;
101:843–7.
3. Lellouche N, Jais P, Nault I, et al. Early recurrences after atrial
fibrillation ablation: prognostic value and effect of early reablation.
J Cardiovasc Electrophysiol 2008;19:599–605.
4. Sauer M, Tews J, Schwarzer M, et al. Rapid detection of the R389G
polymorphism of ADRB1 by real time PCR using fluorescence
resonance energy transfer. Clin Lab 2009;55:128–36.
5. Oral H, Knight BP, Ozaydin M, et al. Clinical significance of early
recurrences of atrial fibrillation after pulmonary vein isolation. J Am
Coll Cardiol 2002;40:100–4.
6. Lee SH, Tai CT, Hsieh MH, et al. Predictors of early and late
recurrence of atrial fibrillation after catheter ablation of paroxysmal
atrial fibrillation. J Interv Card Electrophysiol 2004;10:221–6.
7. McCabe JM, Smith LM, Tseng ZH, et al. Protracted CRP elevation
after atrial fibrillation ablation. Pacing Clin Electrophysiol 2008;31:
1146–51.
8. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denerva-
tion enhances long-term benefit after circumferential ablation for
paroxysmal atrial fibrillation. Circulation 2004;109:327–34.
9. Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a
genetic locus for familial atrial fibrillation. N Engl J Med 1997;336:
905–11.
0. Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a
genetically heterogeneous disorder. J Am Coll Cardiol 2003;41:2185–92.
1. Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium
channel (SCN5A) variants associated with atrial fibrillation. Circula-
tion 2008;117:1927–35.
2. Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function
mutation in familial atrial fibrillation. Science 2003;299:251–4.
3. Gollob MH, Jones DL, Krahn AD, et al. Somatic mutations in the
connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med
2006;354:2677–88.
4. Ehrlich JR, Zicha S, Coutu P, Hebert TE, Nattel S. Atrial fibrillation-
associated minK38G/S polymorphism modulates delayed rectifier
current and membrane localization. Cardiovasc Res 2005;67:520–8.
5. Husser D, Stridh M, Sörnmo L, Roden DM, Darbar D, Bollmann A.
A genotype dependent intermediate ECG phenotype in patients with
persistent lone atrial fibrillation. Circ Arrhythm Electrophysiol 2009;
2:24–8.
6. Darbar D, Motsinger AA, Ritchie MD, Gainer JV, Roden DM.
Polymorphism modulates symptomatic response to antiarrhythmic
drug therapy in patients with lone atrial fibrillation. Heart Rhythm
2007;4:743–9.
7. Ouyang F, Ernst S, Chun J, et al. Electrophysiological findings during
ablation of persistent atrial fibrillation with electroanatomic mapping
and double Lasso catheter technique. Circulation 2005;112:3038–48.ey Words: atrial fibrillation y gene variants y catheter ablation.
